NAIROBI, Kenya – Global health agencies and research institutions are intensifying efforts to develop vaccines and treatments for the Bundibugyo strain of Ebola as the outbreak continues to raise concerns across parts of Africa.

Unlike the more common Ebola strains for which medical countermeasures exist, the Bundibugyo variant currently has no approved vaccine or treatment. This has prompted an urgent international response involving scientists, pharmaceutical companies, and public health organizations.

Several experimental vaccine candidates are being fast-tracked, including viral-vector and mRNA-based technologies designed specifically to target the Bundibugyo virus. Researchers are also evaluating promising antiviral drugs and antibody therapies that could help reduce severe illness and fatalities.

Health experts say rapid testing, early detection, and continued investment in vaccine research remain critical to controlling the outbreak. International partners are expanding funding and clinical research efforts in hopes of delivering safe and effective solutions as quickly as possible.

The race to develop new Ebola countermeasures highlights the growing importance of global health preparedness and scientific innovation in responding to emerging disease threats.